what's a glp 1 GLP-1 receptor agonists GLP-1 Weight Loss Options |

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Here's what clinicians should know.

Novo Nordisk CEO Mike Doustdar told Jim Cramer about developments in obesity treatment.

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.